Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Eviplera – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Eviplera – Drug Insight, 2019 highlights…
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage
biopharmaceutical company developing novel therapeutics for the
treatment of rare diseases, today announced that the Data Safety
Moni…
– “When-issued” trading of CYCN expected to begin on Nasdaq on March
18, 2019 –
– Separation completion expected April 1, 2019 –
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ironwood
Pharmaceuticals, Inc. (Nasdaq: IRWD…
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,
announced that on March 12, 2019 the Compensation Committee of Puma’s
Board of Directors approved the grant of inducement restricted stock…
CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical
company leveraging its novel technology platforms to develop and
commercialize ready-to-use injectable and infusible drug formulations,
…
Anticipated 2019 Events include Enrollment in the Planned SPR994
Pivotal Phase 3 Clinical Trial and Top-Line Data from SPR720 and SPR206
Phase 1 Clinical Trials in 2H19
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Spero Therapeutics, …
NEWTOWN, Pa.–(BUSINESS WIRE)–Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or
the “Company”), a neurotech company focused on neurological wellness,
today reported financial results for the fourth quarter and full y…
– Enrollment Completed in INVICTUS Pivotal Phase 3 Clinical Study in
Fourth-line and Fourth-line Plus GIST; Top-line Data Expected in
Mid-2019 –
– INTRIGUE Pivotal Phase 3 Clinical Study Initiated in Second-line
…
FREMONT, Calif.–(BUSINESS WIRE)–Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage
biopharmaceutical company, today announced financial results for the
fourth quarter and year ended December 31, 2018, as well as recent
bus…
Lead Tri-specific T cell Activating Construct (TriTAC) candidate,
HPN424, continues to advance in a Phase 1 clinical trial for the
treatment of prostate cancer
Initial public offering, successfull…